Could a safer start to a key CLL drug be possible? new study reexamines the risk
Disease control
Not yet recruiting
This study looks at people with chronic lymphocytic leukemia (CLL) who are about to start treatment with venetoclax, a targeted therapy. Doctors want to see if starting with other drugs first lowers the risk of tumor lysis syndrome, a dangerous side effect where cancer cells brea…
Phase: NA • Sponsor: Private Hospital of Confluent, France • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC